U.S. House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.) last Friday formally announced Rep. Anna Eshoo (D-Calif.) as Health subcommittee chair and Rep. Diana DeGette (D-Colo.) as leader of the Oversight and Investigations subcommittee.
Eshoo, who is based in a Northern California district with a large biotechnology presence, is considered to be largely an ally of the pharmaceutical industry. However, she has not supported the drug industry’s efforts to reign in the 340B program. DeGette has been more active in the 340B arena. She recently co-spearheaded a bipartisan letter to now former U.S. Health and Human Services (HHS) Secretary Azar signed by 243 members of Congress, calling on the department to penalize drug manufacturers for restricting or prohibiting access to 340B discounts at contract pharmacies. DeGette could end up holding hearings on the matter in the new session of Congress.
U.S. House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.) last Friday formally announced Rep. Anna Eshoo (D-Calif.) as Health subcommittee chair and Rep. Diana DeGette (D-Colo.) as leader of the Oversight and Investigations subcommittee.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
